Splenic marginal zone lymphoma (SMZL) has been recognized as a distinctive type of small B cell lymphoma, and defined on the basis of its morphological, phenotypic, clinical and molecular characteristics. In spite of this, the borders of the entity, the homogeneity of the cases and the presumably cell origin of SMZL remain controversial issues. The frequency of mutation in the 5′ non-coding region of the bcl-6 gene has been used as a marker of germinal center derivation, which may be used to establish the molecular heterogeneity of different non-Hodgkin lymphoma ( 
Introduction
Splenic marginal zone lymphoma (SMZL) has been recognized as a distinctive type of small B cell lymphoma, characterized by massive splenic involvement with a peculiar morphology, in which the main findings are a micronodular pattern of infiltration, biphasic cytology and the presence of marginal zone differentiation. [1] [2] [3] Although a molecular hallmark for this entity has yet to be described, a significant percentage of SMZL cases have 7q31-q32 deletions, and all cases lack the cytogenetic findings that are characteristic of other small B cell lymphomas. 4 In spite of general agreement on the main features of this entity, many uncertainties still remain concerning its borderline with other lymphoproliferative syn- dromes, the molecular homogeneity of the cases included and the cellular origin of this tumor. The claimed marginal zone origin of SMZL has therefore now been brought into question, since it has been recognized that the presence of marginal zone differentiation in the spleen is observed in other lymphoproliferative conditions, and that SMZL, when it infiltrates the lymph nodes, lacks this morphological feature. 2, 5 The name of this condition, splenic marginal zone lymphoma, recognizes the existence of a prominent presence of marginal zone in splenic infiltration, and refers to a hypothetical origin in the marginal zone. The marginal zone of the human spleen is a B cell compartment concentric to the mantle zone, and is composed of medium-sized lymphocytes with clear cytoplasm. Their phenotype is IgM Equivalent marginal zone cell populations have also been described in Peyer's patches, tonsilar intraepithelial crypt cells, palatine tonsils and the lymph nodes.
7-10
The investigation of B cell lineage and differentiation has been enormously facilitated by the discovery that B cells in the germinal center suffer somatic hypermutation of bcl-6 and immunoglobulin heavy chain variable region (IgV H ) genes, which in the case of Ig genes increases their affinity with the antigens present in the germinal center microenvironment. [11] [12] [13] [14] [15] Mutation analysis of rearranged IgV H genes in microdissected marginal zone B cells in the spleen, Peyer's patches and lymph nodes has shown that there are mutated IgV H genes in the majority of cells, as well as evidence of related B cell clones. [16] [17] [18] [19] Although it was initially assumed that the process of somatic hypermutation in normal B lymphocytes was restricted to Ig loci, including heavy and light chain variable region genes, 20 analogous mutations in the bcl-6 gene were further described, showing promoter-dependent hypermutations in the noncoding first exon, paralleling and almost identical with the hypermutation of IgV H genes with respect to mutation frequency and the involvement of B cell subpopulations.
21-23
Bcl-6 is a gene located at chromosomal band 3q27, and encodes a POZ/zinc finger transcriptional repressor that is normally expressed in B cells within germinal centers, and which is required for germinal center formation and T celldirected immune response. 24, 25 Several studies have shown that bcl-6 rearrangements occur at an overall frequency of 30-40% in diffuse large B cell lymphoma (DLBCL) and 6-14% in follicular lymphoma (FL). [26] [27] [28] Somatic mutations in the 5′ non-coding region of the bcl-6 gene have been detected in normal germinal center B cells, as well as in lymphomas with a germinal center phenotype. [21] [22] [23] These mutations are found independently of bcl-6 rearrangement in DLBCL and FL. 29, 30 Recent studies indicate that these mutations accumulating in the regulatory region of the bcl-6 gene may play a role in lymphoma progression and in the transformation of FL to more aggressive large cell lymphoma.
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In order to clarify the B cell differentiation stage and the cells originating SMZL, we decided to investigate the presence of hypermutation in the bcl-6 5′ non-coding region gene, while simultaneously analyzing their presumably normal cellular counterparts, microdissecting cells from the germinal center, mantle cells and marginal zone of normal human spleen. To avoid uncertainty in the selection of SMZL cases, we only analyzed cases that showed a typical histology in their splenectomy specimens, thereby excluding cases selected exclusively on the basis of peripheral blood cell morphology.
Materials and methods
Tissue samples
Frozen tissue blocks from 22 cases of SMZL were included in this study. These cases were selected from the routine and consultation files of the Pathology Laboratory of the Virgen de la Salud Hospital (Toledo, Spain), based on the availability of frozen material. These cases were diagnosed on the basis of splenic morphology according to the criteria that are currently used. 33, 34 The percentage of malignant cells was estimated by histological examination and immunohistochemical CD20 staining, and at least 70% of cells were tumoral.
The frozen tissue block of normal spleen was obtained from a splenectomy specimen obtained incidentally in a routine gastrectomy. Histological examination of this reactive spleen showed preserved morphology ( Figure 1) ; while an IgV H PCR study showed polyclonal amplification.
A clinical follow-up was performed in all cases, with a median range of 35 months.
Peripheral blood from eight healthy donors was included in this study as a negative control.
Immunostaining techniques
Monoclonal antibody for CD20 (L-26) and polyclonal antibody for IgD were used. Bcl-6 protein was detected with
Figure 1
Reactive follicle from normal spleen. The germinal center, mantle and marginal zones can be seen.
Leukemia monoclonal antibody (PG-B6p) and CD38 protein was detected with monoclonal antibody (VS38).
After incubation with the primary antibody, immunodetection was performed with peroxidase-labeled streptavidin biotin, using diaminobencidine chromogen as substrate. All immunostaining was performed using the TechMate 500 automatic immunostaining device. All the antibodies and the labelling system were purchased from Dako, Copenhagen, Denmark.
Microdissection
Different areas, the germinal center, mantle zone and marginal zone were identified on a 5 m section stained with a polyclonal antibody directed against IgD (Dako). The sections were digested with 0.5 g/ml collagenase type IV (Sigma, St Louis, MO, USA) in phosphate-buffered saline (PBS) for 2 h at 37°C in a wet chamber.
300 to 500 cells from each subset were dissected using a hydraulic micromanipulator (Eppendorf) (Figure 2 ), and treated with 10 l of PCR buffer (Boehringer Mannheim, Mannheim, Germany) containing 0.25 mg/ml of proteinase K (Sigma) and digested at 50°C for 1 h. Proteinase K was inactivated at 95°C for 10 min, and 5 l of the sample was used for PCR.
PCR
A unique PCR product encompassing fragments E1.10, E1.11 and E1.12 (previously published 29 ) and spanning 790 pb (nucleotides +357 to +1147) (the first nucleotide of the amplified bcl-6 gene region, corresponding to the first nucleotide of the sense primer is arbitrarily defined as position +1) was amplified by 5′-CCGCTGCTCATGATCATTATTT (sense), and 5′-TAGACACGATACTTCATCTCAT (antisense) primers. 22 This fragment is located downstream of the first bcl-6 non-coding exon, and has been shown to harbor Ͼ95% of the mutation in the 5′ non-coding region of the bcl-6 gene detected in B non-Hodgkin's lymphoma. 33 The high-fidelity polymerase Pfu (Promega, Madison, WI, USA) was used to amplify genomic DNA.
The PCR reaction was carried out in a 25 l volume containing 25 pmol of each primer, 200 m dNTPs, 10 mm Tris HCl, 50 mm KCl, 1.5 mm MgCl 2 and 2 U Taq polymerase (Boehringer Mannheim). Conditions of amplification were as follows: 5 min denaturation at 95°C, followed by 30 denaturation cycles of 30 s each at 95°C, 30 s annealing at 57°C and a 1-min extension at 72°C. There was a final step of extension at 72°C for 5 min performed in a Perkin Elmer 2400 GeneAmp PCR system (Norwalk, CT, USA). PCR products were checked for yield and size on 2% agarose gels before further analysis.
Cloning
A cloning strategy was adopted for the analysis of normal B cell subpopulations within the spleen. PCR products were purified using the Wizard PCR Preps kit (Promega) and ligated into a PGEM-T easy vector (Promega). Plasmids with the inserts were transformed into JM109 competent cells (Promega), checked by PCR, purified using the Wizard Plus SV Minipreps Kit (Promega), and directly sequenced.
Sequencing analysis
Direct sequencing was performed from both strands using the same primers as in the amplification, with two additional internal oligonucleotides (E1.24 and E1.23). 29 The direct sequencing procedure was performed using an ABI 310 sequencer (Perkin Elmer, Warrington, UK) following the manufacturer's procedure. Mutations were identified by comparison with the new bcl-6 gene germline sequence 32, 35 which differs in seven positions from the previously published one (Z79581). In all cases of SMZL sequencing, analysis was confirmed by two separate experiments.
Statistical analysis
Survival analyses were performed using the Kaplan-Meier lifetable method. Differences between survival curves were determined according to the log-rank test.
Results
BCL-6 mutation in normal human spleen
A total of 10-15 clones from each cell population were screened for bcl-6 mutation. Mutations were found in 3/10 clones (30%) from the germinal center and 5/14 clones (35%) from the marginal zone. No mutation was found in mantle zone B cells (0/15 clones) ( Table 1 ). The frequency of mutation in the mutated clones ranged from 0.06 to 0.18 × 10 −2 /bp. Two B cell clones from the marginal zone could be related to one of the clones present in the germinal center cells (one Table 1 Percentage of bcl-6 mutation in SMZL and normal B cell subpopulations of the spleen
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Mutated cases (%) with identical mutational patterns and the other with one additional mutation, interpreted as a possible subclone derived from ongoing mutation (Figure 3) . The sequence analysis of this case showed two polymorphisms: deletion (⌬T) at position +876, and a G-C change at position +753, both of which have already been described. 29, 35 Both changes were present in heterozygosity (data not shown).
BCL-6 mutation in SMZL
A total of 22 SMZL cases were investigated for bcl-6 mutation by using direct sequencing. Mutation was found in 3/22 (13%) cases of SMZL (Table 1 ). The characteristics of the bcl-6 mutations detected in SMZL are summarized in Table 2 , and representative results are shown in Figure 4 .
The majority of mutations (8/10) were localized in a region of 340 bp spanning the E1.10 and E1.11 fragments. The mutations were represented by single nucleotide substitution and one deletion, and no point insertion was observed. The substitutions were caused by 44% transition and 55% transversion mutations. The frequency of mutations in mutated SMZL cases ranged from 1 to 6 over the 790 bp analyzed,
Figure 3
Representation of the bcl-6 5′ non-coding region mutations in germinal center, mantle zone and marginal zone clones from normal human spleen. The different clones are indicated by circles. Filled circles represent IgD + clones from mantle zone and empty circles represent IgD − clones from the germinal center and marginal zone. Clonal expansion was observed between two marginal zone clones. corresponding to a frequency of 0.06 to 0.37 × 10 −2 /bp ( Table 2) .
A variety of studies have recognized specific nucleotide motifs within the Ig genes as intrinsic hotspots for somatic hypermutations, and the consensus RGYW (A/G G C/T A/T) appears to be the one that is most frequently mutated. In the bcl-6 locus, the frequency of G mutations within the RGYW motif is inferior to that observed in IgVH. In these cases one of two G substitutions were flanked by the mutation hot motif RGYW.
The two polymorphisms detected in the normal spleen were present in some SMZL cases, as well as in the DNA from the peripheral blood of healthy donors.
In all cases analyzed, a previously described 7 base differLeukemia ence 32, 35 was observed from the reported germline (GenBank accession No. Z79581).
Correlation between bcl-6 mutation and clinical outcome
All three patients with bcl-6 somatic mutation were alive at 36, 40 and 13 months, respectively, after splenectomy, without evidence of tumoral progression. Analysis of the cases without mutations showed an increasing probability of relapse or progression over time, but comparative analysis of both series did not show any significant results, due to the small number of patients with somatic mutation included in this series.
A relationship between CD38 expression and the absence of bcl-6 somatic mutation was not observed in this series, given that CD38 expression was observed in 4/22 cases, one of them with somatic mutation.
Discussion
This study analyzed mutations in the 5′ non-coding region of the bcl-6 gene in SMZL and different cell populations microdissected from human normal spleen.
Previous studies have demonstrated that bcl-6 mutations take place in normal germinal center B cells, and they are therefore regarded as a histogenetic marker of B cell transition through the germinal center in the analysis of lymphomas. 29, 30 Different studies suggest that bcl-6 and IgV H mutations are produced through the same mechanism, in the same cell compartments, 21, 22 and that the difference in the mutability of the IgV H and bcl-6 genes may be attributable to differences in transcription rates or qualitative differences in control elements. 22 Thus essentially the lymphoma types in which IgV H mutations are detected simultaneously display bcl-6 mutations, albeit at a lower frequency. 21, 36 Controversial findings have, nevertheless, been recently published for B-CLL, where the existence of isolated somatic hypermutation of IgV H or bcl-6 genes has been recently demonstrated. This somatic hypermutation was found useful in B-CLL to define a molecular heterogeneity of this entity, which revealed a significant clinical difference. 35, 36 These findings prompted us to evaluate the frequency and distribution of bcl-6 mutations in SMZL and microdissected normal B cell subpopulations.
In this series of SMZL cases, mutations of the 5′ non-coding region of the bcl-6 gene were detected in only 3/22 (13%) of the analyzed cases. The existence of a relative molecular heterogeneity in this condition could be supported by this observation, in which a minority of cases show bcl-6 somatic mutation, at a frequency (0.05%) which is comparable to that of peripheral memory B cells. [21] [22] [23] This is consistent with the hypothesis that a fraction of this lymphoproliferative syndrome derives from post-germinal center cells, while a majority would derive from naive B cells. A similar variability in the frequency of bcl-6 and IgV H somatic mutations has also been observed in a closely related lymphoproliferative condition, B cell chronic lymphocytic leukemia (B-CLL), where cases with IgV H somatic mutation were also characterized by the absence of CD38 expression and a more favorable clinical course. [36] [37] [38] [39] A revision of the frequency of CD38 expression and comparative analysis of the clinical course in our series failed to identify any significant difference, perhaps because of the relatively small size of the group with bcl-6 mutations. Thus, a more comprehensive analysis of a larger group of SMZL cases seems to be warranted by this study, in order to search for other clinical, morphological and phenotypical traits linked to this molecular heterogeneity.
These results contrast with previous studies in which cases of SMZL and splenic lymphoma with villous lymphocytes (SLVL), an overlapping condition, showed somatic mutations of IgV H genes. [40] [41] [42] [43] This difference could be derived from the different criteria used to select cases, the difficulty of accurately recognizing cases of SMZL, or it may also be dependent on the choice of the bcl-6 gene in this series, instead of IgV H . To avoid bias deriving from a low representation of tumoral cells in the analyzed samples, we only studied DNA extracted from splenic samples in which the percentage of B cells was shown to represent over 70% of the cells included in the sample. At the same time the diagnosis of all cases was confirmed in spleen sections, using restrictive histological and immunophenotypical criteria.
The low frequency of bcl-6 mutations in this series differs significantly from the percentage of bcl-6 mutation that other studies have observed in marginal zone lymphoma-mucosaassociated lymphoid tissue (MZL-MALT), DLBCL and FL, where the frequency of mutations ranges from 33% to 60%; this is slightly more frequent than in mantle cell lymphoma (MCL) (5%, 10%) and slightly lower than the percentages of bcl-6 mutations observed in chronic lymphocytic leukemia (CLL) (15-42%) (Table 3) . 21, 31, 35, 36 Previous studies have suggested that bcl-6 mutations may have functional significance, based on their frequency and clustering in the proximity of the bcl-6 promoter. This is supported by in vitro studies showing that mutations may alter the transcriptional activity of bcl-6. 29, 30, 44 The level of expression of bcl-6 in these cases did not differ substantially from expression in non-mutated cases, where bcl-6 is mainly expressed in the germinal center, and at lower intensity in marginal zone cells.
In this study, mutations in the bcl-6 gene have been found in benign germinal centers as well as marginal zone cells of normal spleen. These findings confirm previous data on the frequency of IgV H mutations in the marginal zone cells of the spleen, thereby confirming that at least a significant proportion of splenic marginal zone B cells are composed of memory cells, which is consistent with their IGM + IgD − immunophenotype, suggesting that these cells are post-germinal center B cells (Table 3) . 16, 18 This study has also shown evidence of clonal expansion within the marginal zone. However, the mantle cells of the spleen that were analyzed, selected on the basis of their IgD expression, show a germinal configuration of the bcl-6 gene. This datum coincides with others previously obtained in the analysis of the IgV H and bcl-6 genes, which corroborate that mantle cells in the spleen are naive B cells. 16 The data presented here seem to support the hypothesis that, in spite of initial morphological observations, a significant proportion of SMZL cases could derive from an unmutated naive precursor other than the marginal zone, and possibly situated in the mantle zone of the splenic lymphoid follicles. This is consistent with the high frequency of IgD expression by SMZL cells. This has already been proposed as an explanation for the lack of marginal zone differentiation observed in the lymph nodes involved by SMZL, and the frequent presence of marginal zone differentiation in spleens involved by a variety of types of non-Hodgkin lymphoma. This suggests that such marginal zone differentiation could be dependent on the microenvironmental features of the lymphoid follicles in the spleen, rather than the histogenetic characteristics of the tumor.
